Netupitant or fosnetupitant and palonosetron

(Akynzeo®)

Akynzeo®

Drug updated on 11/16/2023

Dosage FormFor Injection (intravenous; 235 mg fosnetupitant/0.25 mg palonosetron ); Injection (intravenous; 235 mg fosnetupitant/0.25 mg palonosetron); Capsule (oral; 300 mg netupitant/0.5 mg palonosetron)
Drug ClassReceptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Akynzeo capsule is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
  • Akynzeo for injection and Akynzeo injection are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.
  • Akynzeo is a combination of palonosetron, a serotonin-3 (5-HT3) receptor antagonist, and netupitant or fosnetupitant, substance P/neurokinin-1 (NK-1) receptor antagonists: palonosetron prevents nausea and vomiting during the acute phase and netupitant/fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Akynzeo (netupitant/fosnetupitant and palonosetron) Prescribing Information2023Helsinn Therapeutics (U.S.), Inc., Iselin, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines